Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Aura Biosciences Inc AURA

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:AURA)

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 26, 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 12, 2024

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

GlobeNewswire October 17, 2024

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

GlobeNewswire September 12, 2024

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

GlobeNewswire September 3, 2024

Aura Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

GlobeNewswire August 26, 2024

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 8, 2024

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Opinion & Analysis (NDAQ:AURA)

No current opinion is available.

Bullboard Posts (NDAQ:AURA)

Aura Biosciences Reports Positive Phase 2 End of Study Resul

Just In: $AURA Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early...
whytestocks - September 12, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) &#8211; A Promising Pre

http://beyondspx.com/2024/07/31/aura-biosciences-inc-nasdaqaura-a-promising-precision-immunotherapy-player-poised-for-growth/
MikeTester - August 2, 2024